Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan
Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan
复制标题
DOI：
10.1007/s11604-015-0442-1
复制
发表时间：
2015-07-01
影响因子：
2.1
通讯作者：
Nakamura, Ikuo
中科院分区：
文献类型：
--
作者：
Sugimoto, Katsutoshi;Moriyasu, Fuminori;Nakamura, Ikuo
本临床研究旨在评价日本不可逆电穿孔（IRE）治疗肝细胞癌（HCC）患者的安全性和短期结局。5例患者（3例男性和2例女性;平均年龄，66.6 +/- A 5.8岁）共6例HCC入组，并使用经皮超声（US）引导的IRE进行治疗。根据不良事件和实验室检查值评估安全性。在指定点使用全氟丁烷微泡造影剂进行对比增强US、对比增强多相CT和钆塞酸增强MRI（EOB-MRI）评估局部控制。肿瘤直径范围为11至28 mm（平均直径17.5 ± 6.3 mm）。6例肿瘤中的5例（83%）成功治疗，迄今为止没有局部复发（平均随访244 +/- A 55天）。在位于肝1段的1处病变中，通过随访EOB-MRI在干预后7天诊断出残留肿瘤。没有观察到与IRE手术相关的严重并发症，本研究的结果表明，图像引导下经皮IRE可以达到令人满意的局部疾病控制，特别是对于小肝癌，患者耐受性良好。
This clinical study was conducted to evaluate the safety and short-term outcomes of irreversible electroporation (IRE) for the treatment of patients with hepatocellular carcinoma (HCC) in Japan.The study was designed in a prospective setting. Five patients (3 men and 2 women; mean age, 66.6 +/- A 5.8 years) with 6 HCCs were enrolled and treated using percutaneous ultrasound (US)-guided IRE. Safety was assessed based on adverse events and laboratory values. Local control was assessed using contrast-enhanced US with a perflubutane microbubble contrast agent, contrast-enhanced multiphase CT, and gadoxetic acid-enhanced MRI (EOB-MRI) at designated points.The tumors ranged in diameter from 11 to 28 mm (mean diameter, 17.5 +/- A 6.3 mm). Five of the 6 tumors (83 %) were successfully treated, with no local recurrence to date (mean follow-up 244 +/- A 55 days). In 1 lesion located in liver segment 1, residual tumor was diagnosed at 7 days after intervention by follow-up EOB-MRI. No serious complications related to the IRE procedure were observed.The results of this study suggest that image-guided percutaneous IRE can achieve satisfactory local disease control, particularly for small HCCs, and is well tolerated by patients.